Search - Archive ouverte HAL Access content directly

Filter your results

25 Results

Acetylation of Tat defines a CyclinT1-independent step in HIV transactivation

K Kaehlcke , A Dorr , C Hetzer-Egger , V Kiermer , P Henklein et al.
Molecular Cell, 2003, 12 (1), pp.167-176. ⟨10.1016/S1097-2765(03)00245-4⟩
Journal articles hal-01441358v1
Image document

A Low Molecular Weight Protein from the Sea Anemone Anemonia viridis with an Anti-Angiogenic Activity

Erwann Loret , José Luis , Christopher Nuccio , Claude Villard , Pascal Mansuelle et al.
Marine drugs, 2018, 16 (4), pp.134. ⟨10.3390/md16040134⟩
Journal articles hal-01771025v1

Tat HIV-1 Primary and Tertiary Structures Critical to Immune Response Against Non-homologous Variants

Sandrine Opi , Jean-Marie Peloponese , Didier Esquieu , Grant Campbell , Jean de Mareuil et al.
Journal of Biological Chemistry, 2002, 277 (39), pp.35915-35919. ⟨10.1074/jbc.M204393200⟩
Journal articles hal-02137976v1

The C-terminus of HIV-1 Tat modulates the extend of CD178 mediated apoptosis of T cells.

Campbell G.R. Watkins J. Esquieu D. Pasquier E. Loret E.P. And Spector S.A.
Journal of Biological Chemistry, 2005, 280, 46, pp.38376-38382
Journal articles hal-00018388v1

1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein.

Jean-Marie Peloponese , C. Gregoire , S Opi , E Esquieu , James N. Sturgis et al.
Comptes rendus de l’Académie des sciences. Série III, Sciences de la vie, 2000, 323 (10), pp.883-94. ⟨10.1016/S0764-4469(00)01228-2⟩
Journal articles istex hal-02137980v1

A reasonable hope to cure from HIV with the Tat Oyi vaccine: results and follow up of a double blinded randomized phase I/IIa clinical trial in France

Erwann Loret
Vaccines and Immunization, Conference Series, Feb 2017, BERLIN, Germany
Conference papers hal-01448279v1

Full Peptide Synthesis, Purification, and Characterization of Six Tat Variants

Jean-Marie Peloponese , Yves Collette , Catherine Grégoire , Christian Bailly , Daniel Campèse et al.
Journal of Biological Chemistry, 1999, 274 (17), pp.11473-11478. ⟨10.1074/jbc.274.17.11473⟩
Journal articles hal-02137983v1
Image document

HIV Extracellular Tat: Myth or Reality?

Erwann Loret
Current Opinion in HIV and AIDS, 2015
Journal articles hal-03082096v1

Protein from the Sea Anemone Anemonia viridis with an Anti-Angiogenic Activity

Erwann Loret
Marine Compounds and Cancer 2020, In press
Book sections hal-03386339v1

Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.

J.D. Watkins S. Lancelot G.C. Campbell D. Esquieu J. de Mareuil S. Opi S. Annapa J.P. Salles E.P. Loret
Retrovirology, 2006, 3, pp.8
Journal articles hal-00019900v1
Image document

Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells

Fabienne Rayne , Solène Debaisieux , Hocine Yezid , Yea-Lih Lin , Clément Mettling et al.
EMBO Journal, 2010, 29 (8), pp.1348-1362. ⟨10.1038/emboj.2010.32⟩
Journal articles hal-02147182v1

Structure Function Relationships of KTS Disintegrins and Design of Antiangiogenic Drugs

Olfa Kallech-Ziri , José Luis , Ziad Faljoun , Jean-Marc Sabatier , Maxime Lehmann et al.
Letters in Drug Design and Discovery, 2010, 7 (1), pp.36-40. ⟨10.2174/157018010789869325⟩
Journal articles pasteur-01375293v1

Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat

Sonia Mediouni , Krishna Chinthalapudi , Mary Ekka , Ippei Usui , Joseph Jablonski et al.
ChemMedChem, 2019, 10 (1), ⟨10.1002/mbo3.530⟩
Journal articles hal-02080280v1

A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor

Mickaël Montembault , Giang Vo-Thanh , Abdallah Deyine , Valérie Fargeas , Monique Villiéras et al.
Bioorganic and Medicinal Chemistry Letters, 2004, 14 (6), pp.1543-1546. ⟨10.1016/j.bmcl.2003.12.095⟩
Journal articles istex hal-02137964v1

A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade.

Sonia Mediouni , Jennifer D Watkins , Michel Pierres , Angélique Bole , Erwann P Loret et al.
Journal of Biological Chemistry, 2012, epub ahead of print. ⟨10.1074/jbc.M111.319863⟩
Journal articles hal-00685599v1
Image document

A marine virus controls the green algae Ulva lactuca proliferation in the bay of Marseille

Elvenn A Loret , Monica Lluesma , Aurianne Cassien , David Brinvillier , Pierre Henri Villard et al.
2020
Preprints, Working Papers, ... hal-03081997v1

Identification of Structural Elements of a Scorpion α-Neurotoxin Important for Receptor Site Recognition

Noam Zilberberg , Oren Froy , Erwann Loret , Sandrine Cestèle , Dorit Arad et al.
Journal of Biological Chemistry, 1997, 272 (23), pp.14810-14816. ⟨10.1074/jbc.272.23.14810⟩
Journal articles hal-02353198v1

Homonuclear 1 H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein

Catherine Grégoire , Jean-Marie Peloponese , Didier Esquieu , Sandrine Opi , Grant Campbell et al.
Biopolymers, 2001, 62 (6), pp.324-335. ⟨10.1002/bip.10000⟩
Journal articles istex hal-02137978v1

In vitro characterization of peptidoglycan-associated lipoprotein (PAL)-peptidoglycan and PAL-TolB interactions.

E Bouveret , H Bénédetti , A Rigal , E. Loret , C Lazdunski et al.
Journal of Bacteriology, 1999, 181 (20), pp.6306-11
Journal articles hal-02130134v1

Full-length HIV-1 Tat protein necessary for a vaccine

Sandrine Opi , Jean-Marie Peloponese , Didier Esquieu , Jennifer Watkins , Grant Campbell et al.
Vaccine, 2004, 22 (23-24), pp.3105-3111. ⟨10.1016/j.vaccine.2004.01.057⟩
Journal articles istex hal-02137961v1

Two purified and characterized phospholipases A2 from Cerastes cerastes venom, that inhibit cancerous cell adhesion and migration.

Raoudha Zouari-Kessentini , José Luis , Aida Karray , Olfa Kallech-Ziri , Najet Srairi-Abid et al.
Toxicon, 2009, 53 (4), pp.444-53. ⟨10.1016/j.toxicon.2009.01.003⟩
Journal articles pasteur-00612551v1
Image document

Ulva lactuca, A Source of Troubles and Potential Riches

Herminia Dominguez , Erwann Loret
Marine drugs, 2019, 17 (6), pp.357. ⟨10.3390/md17060357⟩
Journal articles hal-02160426v1
Image document

Seaweed and Sea Anemones proteins as a source of new pharmaceutical active principles

Erwann Loret , N Flórez-Fernández , M D Torres , A Grenha , H Domínguez et al.
Marine Niche: Applications in Pharmaceutical Sciences (pp.203-219), 2021, ⟨10.1007/978-981-15-5017-1_11⟩
Book sections hal-03432718v1

APETx1, a new toxin from the sea anemone Anthopleura elegantissima, which blocks voltage-gated HERG potassium channels

S. Diochot , E. Loret , T. Bruhn , L. Béress , M. Lazdunski et al.
Molecular Pharmacology, 2003, 64, pp.59-69
Journal articles hal-00091497v1
Image document

Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

Erwann Loret , Albert Darque , Elisabeth Jouve , Elvenn A Loret , Corinne Nicolino-Brunet et al.
Retrovirology, 2016, 13 (1), ⟨10.1186/s12977-016-0251-3⟩
Journal articles hal-02077548v1